Compare STNE & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STNE | GPCR |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2018 | 2023 |
| Metric | STNE | GPCR |
|---|---|---|
| Price | $10.52 | $54.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $19.07 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 4.0M | 934.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.07 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.45 | $15.80 |
| 52 Week High | $19.95 | $94.90 |
| Indicator | STNE | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 71.79 |
| Support Level | $10.44 | $36.11 |
| Resistance Level | $11.71 | $57.23 |
| Average True Range (ATR) | 0.43 | 2.78 |
| MACD | 0.01 | 0.89 |
| Stochastic Oscillator | 7.81 | 85.13 |
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.